Streetbeat News

Analyst Ratings

GRTS

HC Wainwright & Co. has downgraded Gritstone Bio (NASDAQ:GRTS) from Buy to Neutral and significantly lowered its price target from $4 to $0.5.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 5:37 pm

AMD

Advanced Micro Devices (AMD) has seen a 7.69% decrease in its short percent of float, now at 2.88%. This is lower than its peers' average of 4.48%. The decrease in short interest may indicate a more bullish sentiment towards AMD.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 5:30 pm

ML

MoneyLion shares are trading lower following Oppenheimer's initiation of coverage with a Perform rating.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 5:28 pm

MXL

MaxLinear shares fell after Susquehanna downgraded the stock from Positive to Neutral and reduced its price target from $26 to $15.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 5:27 pm

TFII

Stephens & Co. has downgraded TFI International from Overweight to Equal-Weight and reduced its price target from $176 to $149.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 5:22 pm

BTSG

Guggenheim has maintained its Buy rating on BrightSpring Health (NASDAQ:BTSG) and raised the price target from $15 to $18.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 5:18 pm

SNOW

Snowflake's shares are experiencing a decline following Argus Research's initiation of coverage with a Hold rating.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 5:17 pm

CMG

Market whales have shown a bullish stance on Chipotle Mexican Grill (NYSE:CMG) with significant options trading activity. Despite a recent price drop, analysts have set a target price of $65.0. The next earnings report is due in 28 days.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 5:16 pm

VEEV

Guggenheim analyst Jack Wallace has maintained a Buy rating on Veeva Systems and raised the price target from $233 to $249.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 5:15 pm

SLNO

Stifel analyst Dae Gon Ha has maintained a Buy rating on Soleno Therapeutics and raised the price target from $59 to $74.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 5:14 pm